BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 19594447)

  • 1. Bioluminescent CXCL12 fusion protein for cellular studies of CXCR4 and CXCR7.
    Luker K; Gupta M; Luker G
    Biotechniques; 2009 Jul; 47(1):625-32. PubMed ID: 19594447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Split Gaussia luciferase for imaging ligand-receptor binding.
    Luker KE; Luker GD
    Methods Mol Biol; 2014; 1098():59-69. PubMed ID: 24166368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Scavenging of CXCL12 by CXCR7 promotes tumor growth and metastasis of CXCR4-positive breast cancer cells.
    Luker KE; Lewin SA; Mihalko LA; Schmidt BT; Winkler JS; Coggins NL; Thomas DG; Luker GD
    Oncogene; 2012 Nov; 31(45):4750-8. PubMed ID: 22266857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo imaging of ligand receptor binding with Gaussia luciferase complementation.
    Luker KE; Mihalko LA; Schmidt BT; Lewin SA; Ray P; Shcherbo D; Chudakov DM; Luker GD
    Nat Med; 2011 Dec; 18(1):172-7. PubMed ID: 22138753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging ligand-dependent activation of CXCR7.
    Luker KE; Gupta M; Steele JM; Foerster BR; Luker GD
    Neoplasia; 2009 Oct; 11(10):1022-35. PubMed ID: 19794961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allosteric peptide regulators of chemokine receptors CXCR4 and CXCR7.
    Ehrlich A; Ray P; Luker KE; Lolis EJ; Luker GD
    Biochem Pharmacol; 2013 Nov; 86(9):1263-71. PubMed ID: 23973527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secreted CXCL12 (SDF-1) forms dimers under physiological conditions.
    Ray P; Lewin SA; Mihalko LA; Lesher-Perez SC; Takayama S; Luker KE; Luker GD
    Biochem J; 2012 Mar; 442(2):433-42. PubMed ID: 22142194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential estrogen-regulation of CXCL12 chemokine receptors, CXCR4 and CXCR7, contributes to the growth effect of estrogens in breast cancer cells.
    Boudot A; Kerdivel G; Habauzit D; Eeckhoute J; Le Dily F; Flouriot G; Samson M; Pakdel F
    PLoS One; 2011; 6(6):e20898. PubMed ID: 21695171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CXCL12-CXCR4/CXCR7 Axis in Colorectal Cancer: Therapeutic Target in Preclinical and Clinical Studies.
    Khare T; Bissonnette M; Khare S
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells.
    Heinrich EL; Lee W; Lu J; Lowy AM; Kim J
    J Transl Med; 2012 Apr; 10():68. PubMed ID: 22472349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual-Color Luciferase Complementation for Chemokine Receptor Signaling.
    Luker KE; Luker GD
    Methods Enzymol; 2016; 570():119-29. PubMed ID: 26921944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opposing roles of CXCR4 and CXCR7 in breast cancer metastasis.
    Hernandez L; Magalhaes MA; Coniglio SJ; Condeelis JS; Segall JE
    Breast Cancer Res; 2011; 13(6):R128. PubMed ID: 22152016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CXCR7 controls competition for recruitment of β-arrestin 2 in cells expressing both CXCR4 and CXCR7.
    Coggins NL; Trakimas D; Chang SL; Ehrlich A; Ray P; Luker KE; Linderman JJ; Luker GD
    PLoS One; 2014; 9(6):e98328. PubMed ID: 24896823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The peptidomimetic CXCR4 antagonist TC14012 recruits beta-arrestin to CXCR7: roles of receptor domains.
    Gravel S; Malouf C; Boulais PE; Berchiche YA; Oishi S; Fujii N; Leduc R; Sinnett D; Heveker N
    J Biol Chem; 2010 Dec; 285(49):37939-43. PubMed ID: 20956518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological/pathological functions of the CXCL12/CXCR4/CXCR7 axes in the pathogenesis of bladder cancer.
    Nazari A; Khorramdelazad H; Hassanshahi G
    Int J Clin Oncol; 2017 Dec; 22(6):991-1000. PubMed ID: 29022185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CXCR7 is not obligatory for CXCL12-CXCR4-induced epithelial-mesenchymal transition in human ovarian cancer.
    Zheng N; Liu W; Chen J; Li B; Liu J; Wang J; Gao Y; Shao J; Jia L
    Mol Carcinog; 2019 Jan; 58(1):144-155. PubMed ID: 30259564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CXCR7 prevents excessive CXCL12-mediated downregulation of CXCR4 in migrating cortical interneurons.
    Abe P; Mueller W; Schütz D; MacKay F; Thelen M; Zhang P; Stumm R
    Development; 2014 May; 141(9):1857-63. PubMed ID: 24718993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of CXCL12, CXCR4, and CXCR7 in patients with breast cancer.
    Wu W; Qian L; Chen X; Ding B
    Int J Clin Exp Pathol; 2015; 8(10):13217-24. PubMed ID: 26722521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammatory CXCL12-CXCR4/CXCR7 axis mediates G-protein signaling pathway to influence the invasion and migration of nasopharyngeal carcinoma cells.
    Qiao N; Wang L; Wang T; Li H
    Tumour Biol; 2016 Jun; 37(6):8169-79. PubMed ID: 26715277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The chemokine receptors CXCR4/CXCR7 and their primary heterodimeric ligands CXCL12 and CXCL12/high mobility group box 1 in pancreatic cancer growth and development: finding flow.
    Shakir M; Tang D; Zeh HJ; Tang SW; Anderson CJ; Bahary N; Lotze MT
    Pancreas; 2015 May; 44(4):528-34. PubMed ID: 25872129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.